Smart adjuvants

Expert Review of Vaccines

Volumn 6, Issue 3, 2007, Pages 391-400

  Schmidt, Clint S ^a   Morrow, W John W ^b   Sheikh, Nadeem A ^a  

^a Dendreon   (United States)

^b InBios International Inc   (United States)

Author keywords

Cancer; Cell targeting; Delivery vehicle; Immunostimulation; Sipuleucel T; Toll like receptor

Indexed keywords

ADENYLATE CYCLASE; ADJU PHOS; ALUMINUM HYDROXIDE; ALUMINUM SALT; AMPLIGEN; BIOPOLYMER; CANARYPOX VIRUS VACCINE; CELL WALL SKELETON; CHOLERA TOXIN; COPOLYMER; CPG 7907; CRL 1005; FREUND ADJUVANT; GAG PROTEIN; HEPATITIS C ANTIGEN; IMMUNOLOGICAL ADJUVANT; IMO 2055; INTERLEUKIN 12P70; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 23; INTERLEUKIN 7; ISCOPREP 7.03; L 121; LIPOSOME; MONTANIDE; MUROCTASIN; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; NY ESO 1 ANTIGEN; PHOSPHORYL LIPID A; PROVAX; QS 21; QUIL A; REHYDRAGEL; SAPONIN; SQUALENE; TITERMAX; UNCLASSIFIED DRUG; UNINDEXED DRUG; VAXIMMUNE; VIRUS ANTIGEN; WART VIRUS ANTIGEN;

ANTIGEN PRESENTING CELL; BORDETELLA PERTUSSIS; CD8+ T LYMPHOCYTE; DRUG FORMULATION; DRUG MEGADOSE; EMULSION; EXPRESSION VECTOR; FOOD AND DRUG ADMINISTRATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNE RESPONSE; INFLAMMATION; LISTERIA MONOCYTOGENES; LOW DRUG DOSE; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; REVIEW; SALMONELLA ENTERICA; SALMONELLA TYPHIMURIUM; SKIN DEFECT; TH2 CELL; TUMOR; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CYTOKINES; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; RECEPTORS, PATTERN RECOGNITION; TOLL-LIKE RECEPTORS; VACCINES;

EID: 34250335055     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.6.3.391     Document Type: Review

References (83)

1. Lindblad EB. Aluminium compounds for use in vaccines. Immunol. Cell. Biol. 82(5), 497-505 (2004).
2. Atmar RL, Keitel WA, Patel SM et al. Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparation. Clin. Infect. Dis. 43(9), 1135-1142 (2006).
3. Stephenson I, Zambon MC, Rudin A et al. Phase I evaluation of intranasal trivalent inactivated influenza vaccine with nontoxigenic Escherichia coli enterotoxin and novel biovector as mucosal adjuvants, using adult volunteers. J. Virol. 80(10), 4962-4970 (2006).
4. Wobser M, Keikavoussi P, Kunzmann V, Weininger M, Andersen MH, Becker JC. Complete remission of liver metastasis of pancreatic cancer under vaccination with a HLA-A2 restricted peptide derived from the universal tumor antigen survivin. Cancer Immunol. Immunother. 55(10), 1294-1298 (2005).
5. Saul A, Lawrence G, Allworth A et al. A human Phase 1 vaccine clinical trial of the Plasmodium falciparum malaria vaccine candidate apical membrane antigen 1 in Montanide ISA720 adjuvant. Vaccine 23(23), 3076-3083 (2005).
6. Sheikh NA, Attard GS, van Rooijen N et al. Differential requirements for CTL generation by novel immunostimulants: APC tropism, use of the TAP-independent processing pathway, and dependency on CD80/CD86 costimulation. Vaccine 21(25-26), 3775-3788 (2003).
7. + cytotoxic T lymphocytes towards soluble antigens: immunostimulating-ovalbumin complexes enter the class I MHC-restricted antigen pathway and allow sensitization against the immunodominant peptide. Eur. J. Immunol. 21(6), 1523-1527 (1991).
8. Andersen CS, Dietrich J, Agger EM, Lycke NY, Lovgren K, Andersen P. The combined CTA1-DD/ISCOMs vector is an effective intranasal adjuvant for boosting prior Mycobacterium bovis BCG immunity to Mycobacterium tuberculosis. Infect. Immun. 75(1), 408-416 (2007).
9. Nguyen TV, Yuan L, Azevedo MS et al. High titers of circulating maternal antibodies suppress effector and memory B-cell responses induced by an attenuated rotavirus priming and rotavirus-like particle-immunostimulating complex boosting vaccine regimen. Clin. Vaccine Immunol. 13(4), 475-485 (2006).
10. Morrow WJW, Yang YW, Sheikh NA. Immunobiology of the Tomatine adjuvant. Vaccine 22(19), 2380-2384 (2004).
11. Kato M, McDonald KJ, Khan S et al. Expression of human DEC-205 (CD205) multilectin receptor on leukocytes. Int. Immunol. 18(6), 857-869 (2006).
12. + T cell tolerance. J. Exp. Med. 196(12), 1627-1638 (2002).
13. Bonifaz LC, Bonnyay DP, Charalambous A et al. In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. J. Exp. Med. 199(6), 815-824 (2004).
14. + T cells in a spectrum of human MHC I haplotypes. Proc. Natl Acad. Sci. USA 104(4), 1289-1294 (2007).
15. Ferkol T, Perales JC, Mularo F, Hanson RW. Receptor-mediated gene transfer into macrophages. Proc. Natl Acad. Sci. USA 93(1), 101-105 (1996).
16. Kawakami S, Yamashita F, Nishida K, Nakamura J, Hashida M. Glycosylated cationic liposomes for cell-selective gene delivery. Crit. Rev. Ther. Drug Carrier Syst. 19(2), 171-190 (2002).
17. Arigita C, Bevaart L, Everse LA et al. Liposomal meningococcal B vaccination: role of dendritic cell targeting in the development of a protective immune response. Infect. Immun. 71(9), 5210-5218 (2003).
18. Greenberg ME, Sun M, Zhang R, Febbraio M, Silverstein R, Hazen SL. Oxidized phosphatidylserine-CD36 interactions play an essential role in macrophage-dependent phagocytosis of apoptotic cells. J. Exp. Med. 203(12), 2613-2625 (2006).
19. Rensen PC, Gras JC, Lindfors EK et al. Selective targeting of liposomes to macrophages using a ligand with high affinity for the macrophage scavenger receptor class A. Curr. Drug Discov. Technol. 3(2), 135-144 (2006).
20. Ribi EE, Cantrell JL, Von Eschen KB, Schwartzman SM. Enhancement of endotoxic shock by N-acetylmuramyl-L-alanyl-(L-seryl)- D-isoglutamine (muramyl dipeptide). Cancer Res. 39(11), 4756-4759 (1979). • Seminal work showing that bacterial cell wall components had immunostimulatory potential.
21. Parida SK, Huygen K, Ryffel B, Chakraborty T. Novel bacterial delivery system with attenuated Salmonella typhimurium carrying plasmid encoding Mtb antigen 85A for mucosal immunization: establishment of proof of principle in TB mouse model. Ann. NY Acad. Sci. 1056, 366-378 (2005).
22. Galán JE. Molecular genetic bases of Salmonella entry into host cells. Mol. Microbiol. 20(2), 263-271 (1996).
23. Russmann H, Shams H, Poblete F, Fu Y, Galan JE, Donis RO. Delivery of epitopes by the Salmonella type III secretion system for vaccine development. Science 281(5376), 565-568 (1998).
24. Nishikawa H, Sato E, Briones G et al. In vivo antigen delivery by a Salmonella typhimurium type III secretion system for therapeutic cancer vaccines. J. Clin. Invest. 116(7), 1946-1954 (2006).
25. Kotton CN, Lankowski AJ, Scott N et al. Safety and immunogenicity of attenuated Salmonella enterica serovar Typhimurium delivering an HIV-1 Gag antigen via the Salmonella Type III secretion system. Vaccine 24(37-39), 6216-6224 (2006). • Elegant and pivotal work demonstrating utility of the Salmonella type III secretion system for delivering antigen into the class I processing pathway.
26. Dadaglio G, Morel S, Bauche C et al. Recombinant adenylate cyclase toxin of Bordetella pertussis induces cytotoxic T lymphocyte responses against HLA*0201-restricted melanoma epitopes. Int. Immunol. 15(12), 1423-1430 (2003).
27. Guermonprez P, Khelef N, Blouin E et al. The adenylate cyclase toxin of Bordetella pertussis binds to target cells via the α(M)β(2) integrin (CD11b/CD18). J. Exp. Med. 193(9), 1035-1044 (2001).
28. Preville X, Ladant D, Timmerman B, Leclerc C. Eradication of established tumors by vaccination with recombinant Bordetella pertussis adenylate cyclase carrying the human papillomavirus 16 E7 oncoprotein. Cancer Res. 65(2), 641-649 (2005). • Highlights the dual facet of adenylate cyclase (CyaA) delivering antigen and having immunostimulatory activity.
29. + T cell epitopes and in vivo Th1-polarized T cell priming. J. Immunol. 173(10), 6089-6097 (2004).
30. + T-cell epitopes to dendritic cells and elicits CTL in vivo. Vaccine 23(5), 604-614 (2004). • Ground-breaking paper showing that antigen could be chemically coupled to CyaA and induce cytotoxic T lymphocytes in vivo.
31. Mascarell L, Bauche C, Fayolle C et al. Delivery of the HIV-1 Tat protein to dendritic cells by the CyaA vector induces specific Th1 responses and high affinity neutralizing antibodies in non-human primates. Vaccine 24(17), 3490-3499 (2006).
32. Saiki I, Kamisango K, Tanio Y, Okumura H, Yamamura Y, Azuma I. Adjuvant activity of purified peptidoglycan of Listeria monocytogenes in mice and guinea pigs. Infect. Immun. 38(1), 58-65 (1982).
33. Weiskirch LM, Paterson Y. Listeria monocytogenes: a potent vaccine vector for neoplastic and infectious disease. Immunol. Rev. 158, 159-169 (1997).
34. Schafer R, Portnoy DA, Brassell SA, Paterson Y. Induction of a cellular immune response to a foreign antigen by a recombinant Listeria monocytogenes vaccine. J. lmmunol. 149(1), 53-59 (1992).
35. Ikonomidis G, Paterson Y, Kos FJ, Portnoy DA. Delivery of a viral antigen to the class 1 processing and presentation pathway by Listeria monocytogenes. J. Exp. Med. 180(6), 2209-2218 (1994).
36. Frankel FR, Hegde S, Lieberman J, Paterson Y. Induction of cell-mediated immune responses to human immunodeficiency virus type 1 Gag protein by using Listeria monocytogenes as a live vaccine vector. J. Immunol. 155(10), 4775-4782 (1995).
37. Shen H, Slifka MK, Matloubian M, Jensen ER, Ahmed R, Miller JF. Recombinant Listeria monocytogenes as a live vaccine vehicle for the induction of protective anti-viral cell mediated immunity. Proc. Natl Acad. Sci. USA 92(9), 3987-3991 (1995).
38. Triebel F, Jitsukawa S, Baixeras E et al. LAG-3, a novel lymphocyte activation gene closely related to CD4. J. Exp. Med. 171(5), 1393-1405 (1990).
39. Huard B, Mastrangeli R, Prigent P et al. Characterization of the major histocompatibility complex class II binding site on LAG-3 protein. Proc. Natl Acad. Sci. USA 94(11), 5744-5749 (1997).
40. Huard B, Gaulard P, Faure F, Hercend T, Triebel F. Cellular expression and tissue distribution of the human LAG-3-encoded protein, a MHC class II ligand. Immunogenetics 39(3), 213-217 (1994).
41. El Mir S, Triebel F. A soluble lymphocyte activation gene-3 molecule used as a vaccine adjuvant elicits greater humoral and cellular immune responses to both particulate and soluble antigens. J. Immunol. 164(11), 5583-5589 (2000).
42. Casati C, Camisaschi C, Rini F et al. Soluble human LAG-3 molecule amplifies the in vitro generation of type 1 tumor-specific immunity. Cancer Res. 66(8), 4450-4460 (2006). • In-depth description of the T-cell specific expansion effect of soluble lymphocyte-activated gene-3.
43. Fougeray S, Brignone C, Triebel F. A soluble LAG-3 protein as an immunopotentiator for therapeutic vaccines: preclinical evaluation of IMP321. Vaccine 24(26), 5426-5433 (2006).
44. Janeway CA Jr, Medzhitov R. Introduction: the role of innate immunity in adaptive immune response. Semin. Immunol. 10(5), 349-350 (1998).
45. Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat. Immunol. 5(10), 987-995 (2004).
46. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu. Rev. Immunol. 21, 335-376 (2003).
47. Padalko E, Nuyens D, De Palma A et al. The interferon inducer ampligen [poly(I)-poly(C12U)] markedly protects mice against coxsackie B3 virus-induced myocarditis. Antimicrob. Agents Chemother. 48(1), 267-274 (2004).
48. Evans JT, Cluff CW, Johnson DA, Lacy MJ, Persing DH, Baldridge JR. Enhancement of antigen-specific immunity via the TLR4 ligands MPL adjuvant and Ribi.529. Expert Rev. Vaccines 2(2), 219-229 (2003).
49. Huleatt J, Jacobs AR, Tang J et al. Vaccination with recombinant fusion proteins incorporating Toll-like receptor ligands induces rapid cellular and humoral immunity. Vaccine 25(4), 763-775 (2007).
50. Levine MM, Ristaino P, Sack RB, Kaper JB, Orskov F, Orskov I. Colonization factor antigens I and II and type 1 somatic pili in enterotoxigenic Escherichia coli: relation to enterotoxin type. Infect. Immun. 39(2), 889-897 (1983).
51. Lycke N, Karlsson U, Sjolander A, Magnusson KE. The adjuvant action of cholera toxin is associated with an increased intestinal permeability for luminal antigens. Scand. J. Immunol. 33(6), 691-698 (1991).
52. Wu HY, Russell MW. Comparison of systemic and mucosal priming for mucosal immune responses to a bacterial protein antigen given with or coupled to cholera toxin (CT) B subunit, and effects of pre-existing anti-CT immunity. Vaccine 12(3), 215-222 (1994).
53. Staats HF, Ennis FA Jr. IL-1 is an effective adjuvant for mucosal and systemic immune responses when coadministered with protein immunogens. J. Immunol. 162(10), 6141-6147 (1999).
54. Eberlein TJ, Rodrick ML, Massaro AF, Jung SE, Mannick JA, Schoof DD. Immunomodulatory effects of systemic low-dose recombinant interleukin-2 and lymphokine-activated killer cells in humans. Cancer Immunol. Immunother. 30(3), 145-150 (1989).
55. West WH, Tauer KW, Yannelli JR et al. Multiple cycles of constant infusion recombinant interleukin-2 in adoptive cellular therapy of metastatic renal carcinoma. Mol. Biother. 1(5), 268-274 (1989).
56. Dybul M, Hidalgo B, Chun TW et al. Pilot study of the effects of intermittent interleukin-2 on human immunodeficiency virus (HIV)-specific immune responses in patients treated during recently acquired HIV infection. J. Infect. Dis. 185(1), 61-68 (2002).
57. Kuwabara K, Nishishita T, Morishita M et al. Results of a Phase I clinical study using dendritic cell vaccinations for thyroid cancer. Thyroid 17(1), 53-58 (2007).
58. Shaw DM, Connolly NB, Patel PM et al. A Phase II study of a 5T4 oncofoetal antigen tumour-targeted superantigen (ABR-214936) therapy in patients with advanced renal cell carcinoma. Br. J. Cancer 96(4), 567-574 (2007).
59. Smith KA, Andjelic S, Popmihajlov Z et al. Immunotherapy with canarypox vaccine and interleukin-2 for HIV-1 infection: termination of a randomized trial. PLoS Clin. Trials 2(1), e5 (2007).
60. + memory cell pool. J. Clin. Invest. 115(5), 1177-1187 (2005).
61. + T reg cells. J. Exp. Med. 203(7), 1701-1711 (2006).
62. Trinchieri G, Scott P. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions. Res. Immunol. 146(7-8), 423-431 (1995). • Seminal description of the characterization of interleukin-12p70.
63. + T cells in vivo. J. Immunol. 163(5), 2561-2567 (1999).
64. + T cells that expands in patients receiving interleukin-12. J. Clin. Invest. 102(3), 561-575 (1998).
65. Leonard JP, Sherman ML, Fisher GL et al. Effects of single-dose interleulin-12 exposure on interleukin-12-associated toxicity and interferon-γ production. Blood 90(7), 2541-2548 (1997).
66. Oppmann B, Lesley R, Blom B et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 13(5), 715-725 (2000).
67. Shimozato O, Ugai S, Chiyo M et al. The secreted form of the p40 subunit of interleukin (IL)-12 inhibits IL-23 functions and abrogates IL-23-mediated antitumour effects. Immunology 117(1), 22-28 (2006).
68. Ha SJ, Kim DJ, Baek KH, Yun YD, Sung YC. IL-23 induces stronger sustained CTL and Th1 immune responses than IL-12 in hepatitis C virus envelope protein 2 DNA immunization. J. Immunol. 172(1), 525-531 (2004).
69. Matsui M, Moriya O, Belladonna ML et al. Adjuvant activities of novel cytokines, interleukin-23 (IL-23) and IL-27, for induction of hepatitis C virus-specific cytotoxic T lymphocytes in HLA-A*0201 transgenic mice. J. Virol. 78(17), 9093-9104 (2004).
70. Overwijk WW, de Visser KE, Tirion FH et al. Immunological and antitumor effects of IL-23 as a cancer vaccine adjuvant. J. Immunol. 176(9), 5213-5222 (2006).
71. Cline MJ, Golde DW. Production of colony-stimulating activity by human lymphocytes. Nature 248(450), 703-704 (1974).
72. Burgess AW, Camakaris J, Metcalf D. Purification and properties of colony-stimulating factor from mouse lung-conditioned medium. J. Biol. Chem. 252(6), 1998-2003 (1977).
73. Gough NM, Gough J, Metcalf D et al. Molecular cloning of cDNA encoding a murine haematopoietic growth regulator, granulocyte-macrophage colony stimulating factor. Nature 309(5971), 763-767 (1984).
74. Gasson JC, Weisbart RH, Kaufman SE et al. Purified human granulocyte-macrophage colony-stimulating factor: direct action on neutrophils. Science 226(4680), 1339-1342 (1984).
75. Wong GG, Witek JS, Temple PA et al. Human GM-CSF: molecular cloning of the complementary DNA and purification of the natural and recombinant proteins. Science 228(4701), 810-815 (1985).
76. Mach N, Gillessen S, Wilson SB, Sheehan C, Mihm M, Dranoff G. Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte-macrophage colony-stimulating factor or Flt3-ligand. Cancer Res. 60(12), 3239-3246 (2000).
77. + T cells and suppresses experimental autoimmune thyroiditis. J. Immunol. 170(11), 5511-5522 (2003).
78. Serafini P, De Santo C, Marigo I et al. Derangement of immune responses by myeloid suppressor cells. Cancer Immunol. Immunother. 53(2), 64-72 (2004).
79. Dranoff G, Jaffee E, Lazenby A et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl Acad. Sci. USA 90(8), 3539-3543 (1993). •• Seminal research paper that showed granulocyte-macrophage colony-stimulating factor-transduced cells were able to elicit antitumor-specific immune responses for a prolonged duration.
80. Parmiani G, Castelli C, Pilla L, Santinami M, Colombo MP, Rivoltini L. Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients. Ann. Oncol. 18(2), 226-232 (2006).
81. Small E, Schelhammer PF, Higano C et al. Placebo-controlled Phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J. Clin. Oncol. 24(19), 3089-3094 (2006).
82. Kundi M. New hepatitis B vaccine formulated with an improved adjuvant system. Expert Rev. Vaccines 6(2), 133-140 (2007).
83. The World Health report 2002, published 2004 www.who.int/whr/2004/annex/ en/index.html